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Abstract 19 
 20 
Aberrant activation of RAS oncogenes is prevalent in lung adenocarcinoma, with somatic 21 
mutation of KRAS occurring in ~30% of tumors. Recently, we identified somatic mutation of the 22 
RAS-family GTPase RIT1 in lung adenocarcinoma, but relatively little is known about the 23 
biological pathways regulated by RIT1 and how these relate to the oncogenic KRAS network. 24 
Here we present quantitative proteomic and transcriptomic profiles from KRAS-mutant and 25 
RIT1-mutant isogenic lung epithelial cells and globally characterize the signaling networks 26 
regulated by each oncogene. We find that both mutant KRAS and mutant RIT1 promote S6 27 
kinase, AKT, and RAF/MEK signaling, and promote epithelial-to-mesenchymal transition and 28 
immune evasion via HLA protein loss. However, KRAS and RIT1 diverge in regulation of 29 
phosphorylation sites on EGFR, USO1, and AHNAK proteins. The majority of the proteome 30 
changes are related to altered transcriptional regulation, but a small subset of proteins are 31 
differentially regulated by both oncoproteins at the post-transcriptional level, including 32 
intermediate filament proteins, metallothioneins, and MHC Class I proteins. These data provide 33 
the first global, unbiased characterization of oncogenic RIT1 network and identify the shared 34 
and divergent functions of oncogenic RIT1 and KRAS GTPases in lung cancer. 35 
 36 
Introduction 37 
Somatic mutation of the KRAS proto-oncogene is a prevalent feature of human cancers, 38 
particularly in lung adenocarcinomas where KRAS is mutated in up to 30% of tumors. Cancer-39 
associated variants such as G12V and Q61H alter the normal regulation of KRAS GTPase 40 
activity by disrupting GTP hydrolysis activity or physical interaction with GTPase-activating 41 
proteins (GAPs)1,2, resulting in heightened downstream cellular signaling through the canonical 42 
RAS effector pathways RAF/MEK and PI3K/AKT as well as others. Following the discovery of 43 
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cancer-associated RAS mutations in the 1980s3,4, thousands of studies have delineated the 44 
critical pathways involved in RAS-mediated cellular transformation, metastasis, and metabolism.  45 
 46 
Recently, another RAS-family GTPase gene, RIT1, was found to harbor somatic mutations in 47 
lung cancer5 and myeloid leukemias6. Interestingly, germline RIT1 mutations are found in 48 
families with Noonan Syndrome, a developmental “RAS”-opathy involving altered craniofacial 49 
morphology and cardiac abnormalities7, and which can also be caused by germline mutations in 50 
KRAS itself or other RAS-pathway genes such as SOS1, SOS2, LZTR1 and SHOC2 51 
(https://omim.org/). In cancer and development, RIT1 mutations are found in cases that lack 52 
canonical KRAS mutations, suggesting that RIT1 may impart the same phenotypes conferred by 53 
activation of RAS. 54 
 55 
Prior studies have characterized the role of RIT1 in neural development8 and we and others 56 
have described the role of mutant RIT1 in cellular transformation5,9,10, knowledge of the function 57 
of cancer- and Noonan-associated RIT1 variants is relatively limited. Unlike KRAS, RIT1 58 
mutations are rarely observed near the critical glycine residues involved in GTP hydrolysis (e.g. 59 
G12 and G13 in KRAS or G30 and G31 in RIT1). Instead, RIT1 mutations occur most frequently 60 
near the switch II domain, also targeted by Q61 KRAS variants (Fig. 1a). Nevertheless,  these 61 
mutations may enhance GTP-bound levels of RIT111,12. The molecular consequences of RIT1 62 
switch II domain mutations may additionally be linked to the loss of RIT1’s physical interaction 63 
with LZTR1, a ubiquitin-conjugating enzyme responsible for degradation of RIT111. Cancer- and 64 
Noonan-associated RIT1 variants lose the ability to interact with LZTR1 and consequently are 65 
highly overexpressed, resulting in increased signaling activity through the RAF/MEK pathway11.  66 
 67 
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4 
Prior studies of RIT1 function focus on candidate cellular signaling pathways based on RIT1’s 68 
homology to KRAS. To our knowledge, unbiased mapping of downstream RIT1-regulated 69 
pathways has not been performed to date. Here we sought to broadly describe the proteome, 70 
phosphoproteome, and transcriptome changes induced by wild-type RIT1 and RIT1M90I, a 71 
cancer- and Noonan-associated variant, and to compare these changes to those induced by 72 
oncogenic KRAS variants. With a particular interest in the consequences of RIT1M90I in lung 73 
cancer, we profiled the effects of RIT1M90I mutation in AALE cells, a non-transformed, 74 
immortalized, human lung epithelial cell line13.  75 
 76 
By comparing the downstream pathways regulated by oncogenic KRAS and RIT1, we uncover 77 
previously unknown consequences of RIT1 activation, such as induction of the epithelial-to-78 
mesenchymal transition (EMT) and post-translational regulation of HLA protein expression. In 79 
addition, we uncover additional functional differences between KRAS and RIT1 including a 80 
distinct and unique role of KRAS mutants in regulation of EGFR and USO1 phosphorylation.  81 
These data provide the first systems-level view of RIT1 and RIT1M90I function. 82 
 83 
Results 84 
 85 
Multi-omic profiling of RIT1- and RAS-transformed human lung epithelial cells 86 
We previously demonstrated that RIT1M90I and other cancer-associated RIT1 variants can 87 
promote cellular transformation of NIH3T3 cells in vitro and in vivo5. To determine whether 88 
RIT1M90I was capable of transforming human lung epithelial cells, we expressed mutant RIT1 or 89 
KRAS in the human lung epithelial cell line, AALE. Similar to our previous findings in rodent 90 
cells, both RIT1M90I and KRASG12V enabled AALE cells to form colonies in soft agar (Fig. 1b).  91 
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The canonical function of oncogenic RAS variants is the downstream activation of the 93 
RAF/MEK/ERK cellular signaling cascade14, and RIT1 shares the ability to bind C-RAF and 94 
induce transcription of ERK target genes activity11. To determine if such regulation is active in 95 
AALE cells, we stably expressed wild-type RIT1 or KRAS, or the mutant forms RIT1M90I, 96 
KRASG12V, and KRASQ61H in AALE cells. KRASQ61H was included since this mutant more closely 97 
resembles the switch II domain mutants observed in RIT1 in cancer (Fig. 1a). RIT1M90I, 98 
KRASG12V, and KRASQ61H all enhanced ERK phosphorylation compared to their respective wild-99 
type protein or vector control (Fig. 1c). Interestingly, wild-type RIT1 overexpression also 100 
modestly enhanced ERK phosphorylation whereas wild-type KRAS suppressed basal ERK 101 
phosphorylation.  102 
 103 
To systematically characterize the signaling networks perturbed by mutant RIT1 and KRAS in 104 
lung cancer, we expressed each variant in AALE cells and performed both RNA-seq and deep 105 
proteome and phosphoproteome profiling by liquid chromatography tandem mass spectrometry 106 
(LC-MS/MS). Following trypsin digestion, peptides were labeled with tandem mass tag (TMT) 107 
reagents in two overlapping 10-plex sets for relative quantification of proteome and 108 
phosphopeptides by LC-MS/MS (Fig. 1d and Supplementary Fig. 1a-b). Following basic 109 
reverse phase chromatography, fractions were either directly subjected to LC-MS/MS for total 110 
proteome quantification, or subjected to immobilized metal affinity chromatography (IMAC) to 111 
enrich for phosphopeptides and then subjected to LC-MS/MS, or. In total, we identified 10,131 112 
proteins, 9002 of which were detected and quantified in every sample, and  29,140 113 
phosphopeptides, 12,325 of which were identified in common in every sample (Supplementary 114 
Tables 1 and 2 and Supplementary Files 1 and 2).  115 
 116 
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In parallel, we generated deep transcriptome profiles of the same isogenic cell lines. 117 
Transcriptome profiling was performed in triplicate on the Illumina NovaSeq platform to a 118 
median read-depth per replicate of 70.1 million reads (Fig. 1e, Supplementary Table 3 and 119 
Supplementary Fig. 1e). No compensatory feedback regulation of RIT1 to KRAS or vice versa 120 
was observed (Fig. 1f). Despite relatively low protein expression of KRAS variants in the AALE 121 
lines (Fig. 1c), the majority of KRAS transcripts in each isogenic cell line corresponded to G12V 122 
or Q61H variants, respectively, with 84.1% of reads harboring the G12V variant in KRASG12V 123 
cells, and 73.3% of reads corresponding to the Q61H allele in KRASQ61H cells (Fig. 1g). As 124 
expected, known KRAS-regulated gene sets were strongly up- and down-regulated in KRAS-125 
mutant cells (Supplementary Fig. 1d).  126 
 127 
Multi-omic profiling identifies global similarity between signaling regulated by RIT1M90I 128 
and oncogenic KRAS 129 
Differentially abundant proteins were identified by comparison to the vector control cells using a 130 
two-tailed moderated t-test (Fig. 2a). Selected proteins observed to be significantly modulated 131 
by LC-MS/MS were cross-validated by Western blot. FOSL1, also known as FRA1, is a basic 132 
leucine zipper transcription factor in the FOS family15. Activation of RAS is known to promote 133 
transcriptional upregulation and protein stabilization of FOSL116,17. By LC-MS/MS, FOSL1 was 134 
markedly overexpressed in KRASG12V, KRASQ61H, and RIT1M90I-mutant cells compared to wild-135 
type cells or vector control cells (Fig. 2b). Consistently, Western blot of independently-derived 136 
AALE isogenic lines demonstrated greater abundance of FOSL1 in KRAS- or RIT1-mutant cells 137 
compared to wild-type expressing cells (Fig. 2b). TXNIP is an inhibitor of thioredoxin involved in 138 
both redox regulation and glucose metabolism18,19. Prior literature identified HRASG12V-induced 139 
suppression of TXNIP transcription and protein translation20,21. TXNIP was among the top down-140 
regulated proteins in KRAS- and RIT1-mutant proteomes, and was decreased in Western blot 141 
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7 
analysis of independently derived cells (Fig. 2c). These validation data demonstrate the utility of 142 
LC-MS/MS to describe protein expression changes and additionally suggest the mechanism of 143 
RAS-mediated modulation of FOSL1 and TXNIP is shared with RIT1M90I.  144 
 145 
Next we compared the global effects of RIT1WT and RIT1M90I to that of KRASWT and KRAS 146 
variants. Proteome and phosphoproteome data from RIT1M90I-expressing cells were highly 147 
correlated with KRASG12V and KRASQ61H profiles, suggesting largely similar downstream 148 
consequences (r = 0.70-0.80 and 0.72-0.75 for proteome and phosphoproteome, respectively; 149 
Fig. 2d). Despite differences in KRAS protein abundance, KRASG12V and KRASQ61H proteomes 150 
and phosphoproteomes were highly correlated (proteome r = 0.85 and phospho r = 0.79; Fig. 151 
2d). In contrast, wild-type KRAS replicates were the most divergent of all profiles, showing 152 
limited correlation to either the KRAS-mutant profiles or RIT1 profiles.  153 
 154 
A recent study found that RIT1 variants, including M90I, may function by relieving negative 155 
regulation of RIT1 by a LZTR1-dependent proteasomal degradation mechanism11. Accordingly, 156 
overexpression of wild-type RIT1 should largely phenocopy expression of RIT1M90I. Consistent 157 
with this idea, RIT1WT cells more closely resembled both RIT1M90I and KRAS-mutant  cells than 158 
KRASWT cells (Fig. 2d). These data highlight a critical divergence between KRAS and RIT1: 159 
expression of wild-type KRAS is not capable of activating downstream oncogenic pathways, 160 
whereas expression of wild-type RIT1 in part resembles activation of RIT1 or KRAS by 161 
mutation. We confirmed this observation in a principal component analysis of transcriptome 162 
data, which further revealed a high degree of similarity between RIT1WT and RIT1M90I-regulated 163 
gene expression (Fig. 2e and Supplementary Table 4).  164 
 165 
 166 
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8 
Oncogenic RIT1  promotes epithelial-to-mesenchymal transition 167 
To identify the downstream pathways regulated by oncogenic KRAS and RIT1, we performed 168 
gene set overlap analysis using MSigDB Hallmark Pathway gene sets22 (Fig. 3a). The epithelial-169 
to-mesenchymal transition (EMT) pathway was the most significant gene set enriched among 170 
up-regulated proteins for both KRASG12V/KRASQ61H  and RIT1WT/RIT1M90I cell lines. EMT is a 171 
cellular transdifferentiation process promoted by cell-extrinsic signaling proteins and 172 
orchestrated by activation of transcription factors such as Twist, Snail, and Zeb family 173 
transcription factors23. It has long been observed that oncogenic RAS proteins, including KRAS 174 
mutants, promote EMT. An EMT-signature is associated with KRAS dependence24, which has 175 
been functionally linked to activation of FOSL125. Interestingly, we find both RIT1M90I and 176 
KRASG12V/KRASQ61H are capable of promoting expression changes of key EMT markers, 177 
including up-regulation of Vimentin, N-Cadherin, and Fibronectin, and downregulation of Keratin 178 
19 (Fig. 3b and Supplementary Fig. 2a). Although canonical EMT transcription factors Snail 179 
(SNA1) and Slug (SNA2) were not detected by proteomic analysis, transcriptomes from RIT1- 180 
and KRAS-mutant cells showed increased activity of these EMT transcription factors as 181 
determined by ChEA3 transcription factor enrichment analysis (Fig. 3c-d and Supplementary 182 
Fig. 2b). To our knowledge, this is the first demonstration of mutant RIT1 promoting EMT in any 183 
cell type.  184 
 185 
Oncogenic KRAS and RIT1 suppress Class I MHC expression via a post-transcriptional 186 
mechanism 187 
Among the top suppressed proteins with differential abundance in both mutant KRAS and 188 
RIT1M90I cells, were major histocompatibility complex (MHC) proteins. Class I MHC proteins 189 
HLA-A, HLA-B, HLA-C, and HLA-F were potently suppressed by KRASG12V, KRASQ61H, and 190 
RIT1M90I (Fig. 4a-b and Supplementary Fig. 3a). Recently there has been a renewed interest 191 
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9 
in expression of immune modulatory proteins in cancer due to the appreciation of the potent role 192 
of the immune system in shaping cancer evolution. Further understanding the regulation of HLA 193 
expression in cancer is particularly critical in metastatic KRAS-mutant lung adenocarcinoma, 194 
where chemotherapy combined with immune checkpoint blockade is often used in the first-line 195 
setting.  196 
 197 
Class I MHC genes HLA-A, HLA-B, and HLA-C harbor loss-of-function mutations in cancer26, 198 
demonstrating selective pressure to lose MHC function during tumorigenesis. Both MHC 199 
expression loss and upregulation of the immune suppressive protein PD-L1 enable tumor 200 
evasion of T-cell recognition of aberrant cancer cell proteins27. Moreover, expression loss of 201 
HLA proteins or B2M, another MHC Class I complex protein, is associated with resistance to 202 
immunotherapy in cancer28. We found that RIT1M90I, KRASG12V, and KRASQ61H cells all promoted 203 
loss of B2M protein abundance in addition to HLA protein loss (Fig. 4c).  204 
 205 
Class I MHC expression is known to be dynamically regulated by upstream signals controlled by 206 
interferon gamma exposure, NF-kB signaling, and chromatin regulators such as EZH229,30. Each 207 
of these mechanisms involves transcriptional regulation of class I MHC genes. However, there 208 
were no transcriptional differences in HLA genes in the KRAS-mutant and RIT1-mutant cells nor 209 
were any transcriptional differences observed in the upstream regulators of MHC Class I 210 
expression NLRC5 and IRF1 and IRF2 (Supplementary Fig. 3b).  Moreover, we excluded the 211 
possibility that lentiviral transduction or expression of a foreign antigen was responsible for the 212 
HLA suppression, because HLA protein expression was maintained or enhanced in RIT1WT-213 
expressing cells as well as vector control cells, which express the Renilla luciferase gene.  214 
 215 
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10 
To identify the possible mechanism of RIT1M90I- and KRAS-mediated MHC suppression, we 216 
identified other proteins that, like HLA, were upregulated in RIT1WT cells but suppressed in 217 
RIT1-mutant and KRAS-mutant cells (Fig. 4d). This analysis revealed the pervasive 218 
downregulation of the Rab-mediated ER/Golgi vesicle-trafficking pathway that controls MHC 219 
Class I processing and presentation as well as the MHC Class I complex proteins themselves 220 
(Fig. 4e). In addition, expression of the proteasomal subunit PSMB9 correlated with loss of the 221 
MHC processing machinery (Fig. 4f and Supplementary Fig. 3c). Loss of PSMB9, also known 222 
as LMP2, has been previously linked to loss of MHC expression after oncogenic 223 
transformation31. We conclude that RIT1M90I and KRASG12V/KRASQ61H suppress MHC Class I 224 
expression through a post-transcriptional mechanism possibly involving PSMB9. Further 225 
investigation of MHC Class I expression loss driven by these oncogenic RIT1 and KRAS is 226 
critical to better understand the role of RAS and RIT1 signaling on immune evasion in cancer.  227 
 228 
The identification of a major class of proteins regulated at the post-transcriptional level in RIT1- 229 
and KRAS-transformed lung epithelial cells brought to our attention the possibility of other post-230 
transcriptional regulation by RIT1 and KRAS. Indeed, oncogenic RAS signaling profoundly 231 
alters cap-dependent translation via activation of the p90 ribosomal S6 kinases (RSKs)32 and 232 
PI3K/mTOR33, so differential protein translation could significantly contribute to altered protein 233 
abundance in RAS-transformed cells. To determine whether there were other protein classes in 234 
addition to MHC Class I proteins with significant post-transcriptional regulation, we performed a 235 
global correlation analysis of the transcriptome and proteome. Significant linear correlations 236 
between transcript and protein abundance were observed for RIT1 and KRAS variants, with the 237 
correlation highest for cells expressing mutant KRASG12V (r = 0.3725) or KRASQ61H (r = 0.3620) 238 
(Fig. 4g). While expression of the majority of genes were correlated at the RNA and protein 239 
levels, the metallothionein protein family including MT1E, MT1F and MT1X was highly 240 
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11 
upregulated in the proteome but not transcriptome of KRAS-mutant cells (Fig. 4g). In addition, 241 
intermediate filament proteins were also substantially regulated post-transcriptionally; both 242 
alpha-internexin (INA) and vimentin (VIM) were expressed more highly in the proteome than 243 
expected from RNA-seq data (Fig. 4g). These data highlight the utility of LC-MS/MS to identify 244 
protein abundance changes that would not be predicted from transcriptome analysis.  245 
 246 
Phosphoproteome profiling illuminates shared and unique signaling by RIT1 and KRAS 247 
Protein phosphorylation is a reversible and dynamic mechanism of intracellular signaling that 248 
enables rapid intracellular transduction of signals controlling cell proliferation, survival, and 249 
metabolism. Although both RIT1 and KRAS act as GTPase switches, they both stimulate 250 
activation of cellular protein kinases such as BRAF. We therefore evaluated protein 251 
phosphorylation regulated by wild-type and mutant RIT1 and KRAS. Phosphosite abundance 252 
was expressed as a relative abundance normalized to the total protein abundance for each 253 
phosphoprotein. Unsupervised hierarchical clustering of the phospho-signatures identified the 254 
RIT1M90I phosphoproteome as most similar to KRASG12V and KRASQ61H phospho-signatures 255 
(Supplementary Fig. 4a). We performed Kinase-Substrate Enrichment Analysis (KSEA34), 256 
which uses kinase-substrate pairings from PhosphoSitePlus35 and NetworKIN36 to identify 257 
differential phosphorylation of kinase-substrate families (Supplementary Table 5). These data 258 
further confirmed the similarity in phosphorylation state between RIT1-mutant and KRAS-mutant 259 
cells. The top kinases with increased substrate phosphorylation in RIT1-mutant and KRAS-260 
mutant cells were ribosomal S6 kinase (RPS6KA1), Protein kinase C (PRKCA), AKT1, and 261 
MAPKAPK2 (Fig. 5a-c, Supplementary Fig. 4b-e, and Supplementary Table 5). The levels of 262 
phosphorylation of RPS6KA1 and MAPKAPK2 substrates were enhanced most strongly in the 263 
mutant cells and less in RIT1 WT and KRAS WT-expressing cells (Fig. 5b-c). Substrates of 264 
Aurora kinase B and CDK1 and PAK1 were suppressed in RIT1- and KRAS-mutant cells (Fig. 265 
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5a and Supplementary Fig. 4b-c and Supplementary Fig. 4f). Although the total 266 
phosphorylation of each substrate reflects the balance between kinases and phosphatases in 267 
the cell, these data suggest that RIT1M90I, like oncogenic KRAS, can activate the canonical RAS 268 
effector pathways involving S6 kinase and AKT.  269 
 270 
Next we assessed the divergent functions of RIT1M90I and KRASG12V/KRASQ61H by identifying 271 
proteins with differential phosphorylation in KRAS-mutant versus RIT1M90I-mutant cells. 902 272 
differentially phosphorylated sites were identified by two-tailed t-test and multiple hypothesis 273 
correction (Fig. 5d; FDR < 0.05). Interestingly, the top site with lower phosphorylation in 274 
KRASG12V and KRASQ61H cells was EGFR serine 1026 (Fig. 5d). In lung adenocarcinoma, KRAS 275 
mutations and EGFR mutations are mutually exclusive, suggesting a powerful genetic 276 
interaction between these two genes.  Recent work demonstrated that mutant KRAS and EGFR 277 
display synthetic lethality37. However the mechanism underlying this lethality is unknown. 278 
Further inspection of the phospho-proteome signatures revealed extensive alteration of EGFR 279 
phosphorylation by KRASG12V and  KRASQ61H, but not by RIT1M90I. 11 of 12 EGFR sites detected 280 
by LC-MS/MS occur in the cytoplasmic carboxy-terminal tail of EGFR (Fig. 5e). Five of these 281 
sites (S991, S991/T993 double phosphorylation, S1026, S1039, and T1041/S1045 double 282 
phosphorylation) were significantly depleted of phosphorylation in KRASG12V and KRASQ61H-283 
expressing cells but not in RIT1M90I-expressing cells. Interestingly, these sites lie in a region of 284 
EGFR that is involved in receptor internalization and endocytosis38 and a phosphorylation-285 
deficient mutant at S991 is defective at internalization39. Consistently, EGFR protein abundance 286 
was increased in KRAS-mutant cells (Supplementary Fig. 4g) Although the specific regulatory 287 
mechanisms leading to this depletion remain unknown, these data point to the existence of 288 
feedback regulatory signaling from oncogenic KRAS to EGFR.  289 
 290 
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13 
Examining phosphorylation uniquely promoted by KRASG12V and KRASQ61H, we identified USO1 291 
phosphorylation at S48 as one of the top most significantly increased phosphorylation events in 292 
KRAS-mutant cells. USO1, also known as p115, is a vesicle tethering factor involved in ER-293 
Golgi intracellular trafficking40.  Although wild-type KRAS and KRAS-mutant proteomic 294 
signatures were largely divergent, USO1 serine 48 phosphorylation was promoted by both 295 
KRASWT and mutant KRAS (Fig. 5f). KRAS relies on vesicle trafficking to ensure proper post-296 
translational farnesylation and palmitoylation, which are required for targeting of KRAS to the 297 
plasma membrane41. We hypothesized that USO1 S48 phosphorylation was therefore 298 
correlated with KRAS expression rather than activity. Indeed, a significant correlation was 299 
observed between overall KRAS expression and USO1 phosphorylation (Fig. 5g). In contrast, 300 
USO1 S48 phosphorylation was only modestly changed in RIT1-mutant cells (Fig. 5d). Notably, 301 
RIT1 lacks the farnesylation and palmitoylation signals present in RAS isoforms42, so the 302 
differential regulation of USO1 by KRAS and RIT1 may be related to differences in RIT1 and 303 
KRAS trafficking.  304 
 305 
Also among the top differentially phosphorylated sites were 32 phosphorylation sites in AHNAK 306 
proteins 1 and 2. AHNAK and AHNAK2 are large scaffolding proteins that have been implicated 307 
as tumor suppressor proteins in breast and lung cancer43,44. Among all phospho-proteins, a 308 
higher proportion (32/117) of sites on AHNAK and AHNAK2 were differentially phosphorylated 309 
than expected by chance (P < 0.0001 by Chi Square test; Supplementary Fig. 4h). Intriguingly, 310 
two recent proximity-labeling proteomic studies identified AHNAK and AHNAK2 as KRAS-311 
interacting proteins45,46, raising the possibility that a direct physical interaction between KRAS 312 
and AHNAK proteins may be involved in the differential AHNAK phosphorylation we observe. 313 
 314 
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14 
Discussion 315 
 316 
Here we describe quantitative proteomic, phosphoproteomic, and transcriptomic datasets that 317 
provide the first systematic view of the RIT1M90I-regulated signaling network. These datasets 318 
were generated from isogenic human lung epithelial cells to provide a physiological view of the 319 
consequences of RIT1 activation in the same cellular compartment that is involved in lung 320 
adenocarcinoma, a tumor type with prevalent mutations in KRAS and RIT1. Broadly, we find 321 
that ‘omic signatures from RIT1M90I-expressing cells largely phenocopy those from cells with 322 
overexpression of wild-type RIT1. This finding lends further support to the notion that oncogenic 323 
RIT1 variants function at least in part through increasing RIT1 abundance11. This is in contrast 324 
to KRAS, where overexpression of wild-type KRAS induces signatures unrelated or opposite to 325 
that of oncogenic KRAS variants G12V and Q61H. The opposing functions of wild-type and 326 
mutant KRAS is consistent with recent evidence suggesting that KRAS functions as a dimer and 327 
that wild-type KRAS directly inhibits the function of oncogenic KRAS variants via physical 328 
dimerization47. This divergence in the function of wild-type RIT1 and KRAS hints at fundamental 329 
differences in molecular regulation of each wild-type GTPase. The ability of RIT1 to promote 330 
downstream RAF/MEK/ERK signaling when aberrantly expressed suggests that RIT1 may not 331 
be subject to the same tight regulation by GTPase-activating proteins (GAPs) that normally 332 
keep RAS in an inactive state. Furthermore, these data raise the possibility that wild-type RIT1 333 
overexpression in RIT1-amplified cancers may contribute to tumorigenesis. RIT1, on 334 
chromosome 1q, is frequently amplified in uterine carcinosarcoma, liver hepatocellular cancer, 335 
cholangiocarcinoma, breast cancer, lung adenocarcinoma, and ovarian cancer. RIT1 mRNA 336 
expression is increased in amplified cases, regardless of tissue type, raising the possibility that 337 
RIT1 overexpression could play a role in tumorigenesis in these cancers. 338 
 339 
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We find that RIT1M90I, KRASG12V, and KRASQ61H share the ability to activate canonical RAS 340 
effector pathways PI3K/AKT and RAF/MEK. Likely as a consequence of RAF/MEK signaling to 341 
FOSL1, RIT1M90I also shares the ability to induce EMT markers including Vimentin, N-cadherin, 342 
and fibronectin. KRAS and RIT1 variants also shared the ability to profoundly suppress HLA-A, -343 
B, and  -C expression via a posttranscriptional mechanism. Taking advantage of differential 344 
expression of HLA proteins between RIT1WT and all other isogenic lines, we identified an entire 345 
Rab-mediated endocytic network that was lost together with HLA proteins in RIT1- and KRAS-346 
mutant cells. This downregulated module also included PSMB9, a subunit of the 347 
immunoproteasome that is involved in antigen processing for class I MHC presentation. RAS 348 
oncogenes have long been recognized to suppress surface MHC expression48, in some cases 349 
transcriptionally and in others post-transcriptionally31. Our data link both oncogenic RIT1 and 350 
RAS to modulation of the processing and trafficking of MHC Class I molecules. Further 351 
identification of the mechanism of RIT1/RAS-mediated MHC suppression will provide a better 352 
understanding of tumor immune evasion which is critically needed to optimize patient 353 
stratification of cancer immunotherapy.  354 
 355 
In addition to the largely concordant regulation of proteins by mutant RIT1 and KRAS, we 356 
identified several unique phosphoproteins with differential abundance in RIT1M90I and KRAS-357 
mutant cells. These included EGFR, a key oncoprotein in lung adenocarcinoma, which showed 358 
reduced phosphorylation of sites involved in receptor internalization and endocytic trafficking. 359 
Given the potent genetic interactions between KRAS and EGFR in lung cancer and colon 360 
cancer, it is attractive to speculate that feedback regulation of KRAS to EGFR could provide an 361 
explanatory mechanism for this phenomenon. Future work is needed to determine the basis of 362 
the specific regulation of EGFR phosphorylation by oncogenic KRAS but not RIT1.  363 
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Together, these results demonstrate the power of quantitative proteomics and transcriptomics to 364 
provide global views of cancer oncogene signaling. Our multi-omic analysis validated known 365 
consequences of RAS activation such as EMT and activation of RAF/MEK and PI3K signaling. 366 
For the first time, we gained a global view of RIT1 function, which confirmed its ability to 367 
stimulate canonical RAS signaling. However, phosphoproteomic profiling identified a number of 368 
key divergent mechanisms between KRAS- and RIT1-mutant cells, which point to the existence 369 
of novel, unique regulators or effectors of KRAS and RIT1 still to be identified. Future work is 370 
needed to investigate the mechanisms of these differences between KRAS and RIT1, the 371 
results of which will have important implications for cancer therapy and Noonan Syndrome. 372 
 373 
 374 
 375 
 376 
  377 
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Methods  378 
 379 
Isogenic Cell Line Generation 380 
Plasmid constructs were cloned using Gateway Technology (Invitrogen/ThermoFisher) using 381 
pLX301 destination vector (Broad Institute) and pDONR223-RIT1 donor vectors previously 382 
described5. Lentivirus was generated by transfection of HEK293T cells with packaging and 383 
envelope vectors using standard protocols.  AALE cells were a kind gift of Jesse Boehm (Broad 384 
Institute). Isogenic cells were generated by transduction of lentivirus generated from pLX317-385 
Renilla luciferase or pLX301-RIT1WT, pLX301-RIT1M90I, pLX301-KRASWT, pLX301-KRASG12V, or 386 
pLX301-KRASQ61H and selection with puromycin. Stable pools of cells were maintained in small 387 
airway growth medium (Lonza).  388 
 389 
Soft Agar Assay 390 
1x105 cells were suspended in 1 ml of 0.33% select agar in small airway growth medium without 391 
EGF (Lonza) and plated on a bottom layer of 0.5% select agar in the same media in six-well 392 
dishes. Each cell line was analyzed in triplicate. Colonies were photographed after 14–21 days 393 
and quantified using CellProfiler49.  394 
 395 
Transcriptome profiling  396 
Three technical replicates per cell line were harvested at ~90% confluence (n = 18 total dishes). 397 
Cells were lysed and total RNA was extracted using Direct-zol RNA Miniprep plus (Zymo 398 
Research). Libraries were constructed using the non-strand-specific poly-A selection Illumina 399 
TruSeq kit for 50bp paired-end reads. Libraries were then pooled and sequenced on the 400 
Illumina NovaSeq platform (Fred Hutch Genomics Core). Reads were aligned to the human 401 
reference genome build hg19/GRCh37 using STAR v.2.5.3a50. Alignments were annotated for 402 
duplicates and read groups, and then reordered and indexed, using Picard Tools v.1.11451. 403 
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Read statistics for each RNA-seq sample were calculated using RSeQC52. Quantification of 404 
gene transcripts was performed by the featureCounts program within the Subread package53, 405 
using hg19 gene annotation from UCSC Gene level CPM and RPKM values were calculated 406 
with edgeR v.3.22.354, and converted into transcripts per million (TPM values with an in-house 407 
script. In total, 12,887 genes were identified with average logCPM at least 0.1 across all 408 
samples. Differential expression analyses comparing KRAS or RIT1 perturbed cell lines against 409 
vector control lines were performed using edgeR54.  410 
 411 
High performance liquid chromatography tandem mass spectrometry (LC-MS/MS) 412 
Cells were washed in ice-cold PBS, scraped into PBS, pelleted, and snap frozen in liquid 413 
nitrogen. The experimental workflow for sample processing, TMT-labeling, peptide enrichment, 414 
and LC-MS/MS were largely as previously described55. Briefly, pellets were lysed in 200 µl of 415 
chilled urea lysis buffer (8 M urea, 75 mM NaCl, 50 mM Tris (pH 8.0), 1 mM EDTA, 2 µg/ml 416 
aprotinin, 10 µg/ml leupeptin, 1 mM PMSF, 1:100 (vol/vol) Phosphatase Inhibitor Cocktail 2, 417 
1:100 Phosphatase Inhibitor Cocktail 3, 10 mM NaF, and 20 µM PUGNAc) for each ~50 mg 418 
portion of wet-weight tissue. Lysates were reduced with 5mM DTT, alkylated with 10 mM IAM, 419 
and digestion performed in solution with 1 mAU LysC per 50 µg of total protein and trypsin at an 420 
enzyme/substrate ratio of 1:49. Reactions were quenched with FA and brought to pH = 3 with 421 
FA. Peptides were desalted on 200 mg tC18 SepPak cartridges and dried by vacuum 422 
centrifugation. 340 µg of peptides were labeled with 10-plex Tandem Mass Tag reagents 423 
(TMT10, Fisher Scientific), according to manufacturer's instructions. To enable quantification of 424 
peptides across all 12 samples, the samples were labeled in sets of 10 across two different 425 
TMT10 pools in a crossover design with 8 of 12 samples analyzed in both TMT10 pools. A 426 
50/50 mix of both AALE vector control lysates was used as an internal reference in both TMT10 427 
runs (Supplementary Fig. 1b). 428 
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 429 
Each TMT10-plex was desalted in a 200 mg tC18 SepPak cartridge and fractionated using 430 
offline HPLC. 5% of each fraction was collected into an HPLC vial for proteome analysis by LC-431 
MS/MS. The remaining 95% was processed for phospho-peptide enrichment via immobilized 432 
metal affinity chromatography (IMAC). IMAC enrichment was performed using Ni-NTA 433 
Superflow Agarose beads incubated with peptides solubilized in a final concentration of 80% 434 
MeCN/0.1% TFA. Phospho-enriched peptides were desalted and collected into an HPLC vial for 435 
analysis by LC-MS/MS. 436 
 437 
Online fractionation was performed using a nanoflow Proxeon EASY-nLC 1200 UHPLC system 438 
(Thermo Fisher Scientific) and separated peptides were analyzed on a benchtop Orbitrap Q 439 
Exactive Plus mass spectrometer (Thermo Fisher Scientific) equipped with a nanoflow 440 
ionization source (James A. Hill Instrument Services, Arlington, MA). In-house packed columns 441 
(20 cm x 75 μm diameter C18 silica picofrit capillary column; 1.9 μm ReprosIl-Pur C18-AQ 442 
beads, Dr. Maisch GmbH, r119.aq; Picofrit 10 μm tip opening, New Objective, PF360-75-10-N-443 
5). Mobile phase flow rate was 200 nL/min, comprised of 3 % acetonitrile/0.1 % formic acid 444 
(Solvent A) and 90 % acetonitrile /0.1 % formic acid (Solvent B). The 110 min LC-MS/MS 445 
method consisted of a 10 min column-equilibration procedure; a 20 min sample-loading 446 
procedure; and the following gradient profile: (min: % B) 0:2; 2:6; 85:30; 94:60; 95:90; 100:90; 447 
101:50; 110:50 (the last two steps at 500 nL/min flow rate). Data-dependent acquisition was 448 
performed using Xcalibur QExactive v2.4 software in positive ion mode at a spray voltage of 449 
2.00 kV. MS1 Spectra were measured with a resolution of 70,000, an AGC target of 3e6 and a 450 
mass range from 300 to 1800 m/z. Up to 12 MS/MS spectra per duty cycle were triggered at a 451 
resolution of 35,000, an AGC target of 5e4, an isolation window of 0.7 m/z, a maximum ion time 452 
of 120 msec, and normalized collision energy of 30. Peptides that triggered MS/MS scans were 453 
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dynamically excluded from further MS/MS scans for 20 sec. Charge state screening was 454 
enabled to reject precursor charge states that were unassigned, 1, or >6. Peptide match was 455 
set to preferred for monoisotopic precursor mass assignment. 456 
 457 
Protein-peptide identification, phosphosite localization, and quantification 458 
MS data was interpreted using the Spectrum Mill software package v6.0 pre-release (Agilent 459 
Technologies, Santa Clara, CA. MS/MS spectra were merged if they were acquired within +/- 45 460 
sec of each other with the same precursor m/z. Also, MS/MS spectra that did not have a 461 
sequence tag length > 0 (i.e., minimum of two masses separated by the in chain mass of an 462 
amino acid) or did not have a precursor MH+ in the range of 750-6000 were excluded from 463 
searching. MS/MS spectra searches were performed against a concatenated UniProt human 464 
reference proteome sequence database containing 58,929 human proteins including isoforms 465 
(obtained 10/17/2014) and 150 additional common laboratory contaminants. ESI-QEXACTIVE-466 
HCD-3 scoring parameters were used for both whole proteome and phosphoproteome datasets. 467 
Spectra were allowed +/- 20 ppm mass tolerance for precursor as well as product ions, 30% 468 
minimum matched peak intensity, and “trypsin allow P” was set as enzyme specificity with up to 469 
4 missed cleavages allowed. Carbamidomethylation at cysteine was set as fixed modification 470 
together with TMT10 isobaric labels at lysine residues (N-termini would be considered 471 
regardless if it was TMT labelled). Acetylation of protein N-termini andoxidized methionine were 472 
set as variable modifications with a precursor MH+ shift range of -18 to 64 Da for the proteome 473 
searches. For the phosphoproteome searches the precursor MH+ shift range was set to 0 to 474 
272 Da and variable modifications of phosphorylation of serine, threonine, and tyrosine. 475 
Identities interpreted for individual spectra were automatically designated as confidently 476 
assigned using the Spectrum Mill autovalidation module to use target-decoy based false 477 
discovery rate (FDR) estimates to apply score threshold criteria. For the whole proteome 478 
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datasets, thresholding was done at the spectral  (< 1.2%)  and protein levels  (< 0.1%) . For the 479 
phosphoproteome datasets, thresholding was done at the spectral (< 1.2%) and phosphosite 480 
levels (< 1.0%). 481 
Replicates across TMT-plexes were highly correlated (Supplementary Fig. 1c) with median 482 
Pearson r = 0.87 and 0.69 for proteome and phosphoproteome, respectively. Technical 483 
replicates and biological replicates were merged to generate final total proteome and phospho-484 
proteome profiles for each isogenic cell line (Supplementary Tables 1 and 2). Replicate-level 485 
profiles are also supplied as JavaScript Object Notation (.json) files that can be visualized and 486 
analyzed using the Morpheus Matrix Visualization and Analysis Software at 487 
https://software.broadinstitute.org/morpheus (Supplementary Files 1 and 2). Differential 488 
protein and phospho-site signatures were generated by computing the mean log2(fold change) 489 
of the abundance of each site in each sample compared to the vector control cells. Statistical 490 
significance of differentially abundant proteins and phosphosites was determined by performing 491 
a one sample moderated t-test with multiple hypothesis correction (Supplementary Tables 1 492 
and 2).  493 
 494 
Integrative Analysis 495 
Correlation of changes in protein expression and changes in RNA expression was modeled 496 
using R’s lm() function. 95% prediction intervals were calculated to determine genes with weak 497 
concordance between protein and RNA expression.  498 
 499 
Gene Set Enrichment Analysis 500 
Analysis of enrichment of KRAS signaling in differential RNA expression profiles was performed 501 
in R with the goseq package56. KRAS signaling gene sets were taken from MSigDB hallmark 502 
gene sets22,57. 503 
.CC-BY-NC-ND 4.0 International licensewas not certified by peer review) is the author/funder. It is made available under a
The copyright holder for this preprint (whichthis version posted April 11, 2020. . https://doi.org/10.1101/2020.04.10.030460doi: bioRxiv preprint 
 
 
 
22 
 504 
Transcription Factor Target Enrichment Analysis 505 
Analysis of over-representation of Transcription Factor targets was performed with ChEA3 by 506 
submitting lists of differentially expressed genes (|LFC| > 1 and FDR < 0.05). ChEA3 performs 507 
Fisher’s Exact Test to compare the input gene set to TF target gene sets in six different 508 
libraries58. Analysis of the Enrichr Queries library was selected as the focus of the present 509 
study. Transcription factors resulting from this analysis were annotated as one of four groups of 510 
EMT association. These four groups were the Snail gene family, confirmed EMT genes defined 511 
by dbEMT59, genes shown to be associated with EMT in at least one study in literature, and 512 
genes unrelated to EMT. 513 
 514 
Antibodies and immunoblotting 515 
Antibodies against FOSL1 (D80B4), TXNIP (D5F3E), and Vimentin (D21H3) were purchased 516 
from Cell Signaling Technology. Vinculin (V9264) was purchased from Sigma Aldrich. 517 
Secondary antibodies StarBright Blue 700 Goat anti-Rabbit IgG, StarBright Blue 520 Goat anti-518 
Rabbit IgG and StarBright Blue 520 Goat anti-Mouse IgG (12005867) were purchased from Bio-519 
Rad. Antibody against RIT1 (#53720) was purchased from Abcam. Cell lysates were prepared 520 
in RTK lysis buffer with protease (11836153001, Roche) and phosphatase (04906837001, 521 
Roche) inhibitors added and quantified by the BCA assay (Thermo Scientific Waltham, MA). 522 
Samples were then boiled in Laemmli buffer (1610747, Bio-Rad, Hercules, CA) and 50 ug of 523 
protein was loaded onto 4-15% Mini-Protean TGX (4561084, Bio-Rad, Hercules, CA) gels. 524 
Protein gels were run and transferred to PVDF membranes (1704274, Bio-Rad, Hercules, CA) 525 
according to manufacturer's instructions. Proteins were detected by specific primary antibody 526 
and secondary antibody then visualized using the ChemiDoc MP Imaging System (Bio-Rad, 527 
Hercules, CA). 528 
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 529 
 530 
KSEA analysis 531 
Kinase-substrate enrichment analysis (KSEA)60 was performed using the KSEA App34 532 
(https://casecpb.shinyapps.io/ksea/) using kinase-substrate mappings from PhosphoSitePlus35 533 
and a p value threshold of < 0.05. A minimum of five detected phospho-site substrates were 534 
needed for kinases to be included in the analysis. The full list of kinase scores and number of 535 
substrates are shown in Supplementary Table 5. 36 kinases had sufficient substrate sites 536 
detected to be included in the analysis. Kinase-substrate mappings are shown in 537 
Supplementary Table 5.  538 
 539 
DATA AVAILABILITY 540 
The RNA-seq data have been deposited in the NCBI Gene Expression Omnibus database with 541 
accession number GSE146479. All mass spectra contributing to this study can be downloaded 542 
in the original instrument vendor format from the MassIVE online repository (Accession number 543 
to be updated prior to publication.) 544 
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Figure Legends 565 
Figure 1. Comparative multi-omic profiling of KRAS- and RIT1-mutant human lung 566 
epithelial cells. a, Protein alignment of KRAS-4B (Uniprot #P01116-2) and RIT1 Isoform 1 567 
(Uniprot #Q92963-1) generated by ClustalW261. Stars indicate the position of the RIT1M90I or 568 
KRASG12V and KRASQ61 variants used in this study. Asterisks indicate fully conserved residues. 569 
Colons indicate strongly conserved residues. Periods indicate weakly conserved residues. b, 570 
Soft agar colony formation assay of isogenic AALE human lung epithelial cells. **, p < 0.01; ****, 571 
p<0.0001 by two-tailed t-test. c, Western blot using anti-RAS and anti-RIT1 antibodies (top 572 
panels), or antibodies against phosphorylated ERK1/2 or vinculin (loading control). SE = short 573 
exposure, LE = long exposure. Isogenic AALE cells were cultured in the presence or absence of 574 
EGF for 12 hours. d, LC-MS/MS workflow for generation of proteome and phosphoproteome 575 
profiles. bRP, basic reverse phase chromatography. IMAC, immobilized metal affinity 576 
chromatography. e,  Workflow for Illumina RNA-seq analysis. f, mRNA quantification in 577 
transcripts per million (TPM) showing mean ± SD of RIT1 (left) or KRAS (right) in isogenic AALE 578 
cells, n = 3 per cell line. *, p < 0.05; ****, p < 0.0001 by two-tailed Student’s t-test compared to 579 
vector control cells. g, RNA-seq quantification of variant allele expression. Data shown is the 580 
percentage of reads at the M90I, G12V, or Q61H variant site for the variant allele or wild-type 581 
allele. 582 
Figure 2. Quantitative proteome and transcriptome profiling identifies similarity in 583 
RIT1M90I-mutant and KRAS-mutant signaling networks. a, Volcano plots of global proteome 584 
data from isogenic AALE cells showing the log2(fold change) (“LFC”) in protein abundance in 585 
each cell line compared to vector control cells. The y-axis displays the negative log10(p value) 586 
calculated from a one sample moderated t-test with multiple hypothesis correction by the 587 
Benjamini-Hochberg method. b, Western blot validation of FOSL1 increased protein abundance 588 
in RIT1- and KRAS-mutant cells. The chart shows the LFC of FOSL1 as determined by LC-589 
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MS/MS. Western blot below shows FOSL1 abundance or Vinculin (loading control). c, Western 590 
blot validation of TXNIP protein abundance in RIT1- and KRAS-mutant cells. The chart shows 591 
the LFC of TXNIP as determined by LC-MS/MS. d, Correlation heatmap showing pairwise 592 
Pearson and Spearman correlations of each proteome and phosphoproteome replicate to every 593 
other replicate. To enable correlation of proteome with phosphoproteome, phosphosites were 594 
collapsed to the protein level by taking the median of all phosphosites for each protein. e, 595 
Principal component analysis (PCA) of RNA-seq data. Circles correspond to control vector or 596 
wild-type replicates. Diamonds correspond to RIT1- or KRAS-mutant profiles. 597 
Figure 3. RIT1M90I promotes epithelial-to-mesenchymal (EMT) transition. a, Gene set 598 
overlap analysis of up-regulated (“Up”; LFC>2) and down-regulated (“down”; LFC<-2) proteins 599 
using MSigDB Hallmark Pathways22. “K” and “R” indicate analysis based on mean LFC of 600 
KRASG12V/KRASQ61H cells or RIT1WT/RIT1M90I cells, respectively. Circle size corresponds to the p 601 
value of gene set overlap analysis determined by MSigDB. b, LFC of protein abundance of EMT 602 
marker genes as determined by LC-MS/MS, relative to vector control cells. c, Transcription 603 
factor target enrichment analysis of differentially expressed genes in RIT1M90I-mutant cells using 604 
Enrichr libraries. FET, Fisher’s exact test. Red = Snail family. Orange = confirmed EMT genes in 605 
dbEMT59. Pale orange = EMT-associated genes in literature. d, Enrichr analysis of KRASG12V-606 
mutant proteome data. Annotation is the same as in c. 607 
Figure 4. RIT1- and KRAS-mutant cells suppress Class I MHC expression via global loss 608 
of antigen processing and presenting machinery. a, Rank plot of all protein abundance 609 
changes in KRASG12V-mutant cells compared to vector control, generated by LC-MS/MS. HLA-610 
A,-B,-C, and -F proteins are labeled in blue. b, Heat map showing HLA protein abundance in 611 
each global proteome replicate. Replicates were clustered by unsupervised hierarchical 612 
clustering using all detected proteins. c, Protein abundance of B2M in LC-MS/MS data. d, Top 613 
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differentially abundant proteins between RIT1WT cells and all other cell lines. Proteins are 614 
ranked by the signal-to-noise (S2N) statistic, shown in the bar chart at the right. e, StringDB62 615 
network analysis of proteins with S2N>2.5 in analysis shown in d.  The network was significantly 616 
more connected than expected by chance (p < 1e-16). Disconnected nodes, single connected 617 
nodes, and disconnected clusters have been removed from the visualization. Edges represent 618 
high confidence interaction scores (>0.9) and network edge thickness indicates the strength of 619 
data support from all StringDB active interaction sources. f, Protein abundance of PSMB9 in LC-620 
MS/MS data. g, Global proteome-transcriptome correlation analysis. A dashed diagonal line 621 
displays the linear regression generated by comparing the LFC of each gene in the 622 
transcriptome to its respective protein LFC in the proteome. The resulting Pearson correlation 623 
coefficient (r) is shown. Genes outside the 95% prediction interval are plotted in red, and include 624 
HLA genes, metallothioneins, and intermediate filament proteins Vimentin (VIM) and alpha 625 
internexin (INA).  626 
Figure 5. Phosphoproteomic profiling illuminates novel differential post-translational 627 
modifications in RIT1M90I- and KRAS-mutant cells. a, KSEA analysis of AALE 628 
phosphoproteomes. Top differentially phosphorylated kinase substrates are shown. The full 629 
KSEA results are shown in Supplementary Fig 4b-c. b, Violin plot of phospho-site abundance 630 
of phospho-sites that are RPS6KA1 substrates. c, Violin plot of phospho-site abundance of 631 
phospho-sites that are MAPKAPK2 substrates. d, Marker selection analysis identifies 632 
differentially phosphorylated sites in KRAS-mutant cells compared to RIT1-mutant cells. 633 
Phosphosites from KRAS-mutant and RIT1M90I-mutant replicate-level phosphoproteome profiles 634 
(Supplementary File 2) were compared by two-tailed t-test. The top 20 significantly (FDR < 635 
0.05) differentially phosphorylated sites in each direction are shown and ranked by t-statistic. A 636 
heat map displays the LFC in phosphorylated peptide abundance of each site compared to 637 
vector control, after normalizing to total protein abundance. e,  LFC of EGFR phosphosites in 638 
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KRAS-mutant and RIT1-mutant cells. Data shown is the mean + SD of n=8 KRAS-mutant 639 
replicates and n=4 RIT1-mutant replicates. *, FDR < 0.01 as determined by two-tailed t-test and 640 
two-stage linear step-up procedure of Benjamini, Krieger and Yekutieli.  f, Relative 641 
phosphorylation of USO1 at serine 48 as determined by LC-MS/MS. Box and whiskers show the 642 
25th-75th percentiles and minimum to maximum of the data, respectively. g, Relationship of 643 
USO1 S48 phosphorylation to KRAS total protein abundance. A dashed line displays the linear 644 
regression fit and gray lines display the 95% confidence interval of the linear model. r = 0.70, p 645 
< 0.01.  646 
 647 
SUPPLEMENTARY FIGURE LEGENDS 648 
Supplementary Figure 1. Workflow and quality control of proteomic and transcriptomic 649 
profiling. a, Replicate-level workflow for tandem mass tag (TMT) labeling and LC-MS/MS. 650 
Lysates from duplicate sets of six isogenic cell lines were used to generate two TMT-plex sets, 651 
with control samples used to link the two sets. b, TMT 10-plex layout showing mass tags 652 
associated with each replicate. c, Average pairwise replicate correlations (Pearson r) of all 653 
replicates from each sample group indicated. d, Enrichment analysis of differentially expressed 654 
genes between KRAS or RIT1 perturbed lines and vector controls using goseq56. mSigDB 655 
hallmark gene sets specific to KRAS signaling are shown. e, RNA-seq run and mapping 656 
statistics show total reads, mapped reads, and reads mapped to rRNA, for each sample. 657 
 658 
Supplementary Figure 2. RIT1 and KRAS promote epithelial-to-mesenchymal transition. 659 
a, Changes in mRNA transcript levels of EMT genes VIM, CDH2, FN1, and KRT19, in each 660 
isogenic cell line compared to vector control. LFC, log2(fold-change) compared to vector cells. b, 661 
Transcription factor target enrichment analysis using Enrichr libraries of differentially expressed 662 
genes in RIT1WT, KRASWT, and KRASQ61H-mutant cells. FET, Fisher’s exact test. Red = Snail 663 
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family. Orange = confirmed EMT genes in dbEMT59. Pale orange = EMT-associated genes in 664 
literature. 665 
 666 
Supplementary Figure 3. Post-transcriptional loss of Class I MHC proteins. a, Rank plot of 667 
all protein abundance changes in KRASQ61H-mutant or RIT1M90I-mutant cells compared to vector 668 
control, generated by LC-MS/MS. HLA-A,-B,-C, and -F proteins are labeled. LFC, log2 fold-669 
change. b, Change in mRNA transcript levels of HLA genes and upstream regulators of MHC 670 
Class I, in each isogenic cell line compared to vector controls. LFC, log2 fold change compared 671 
to vector cells. c, Correlation of protein levels in HLA-A and PSMB9 across each isogenic cell 672 
line. A line is the best-fit linear regression with significant non-zero slope (p < 0.05).  673 
 674 
Supplementary Figure 4. Phosphoproteome profiling identifies enhanced 675 
phosphorylation of specific kinase substrates in KRAS- and RIT1-mutant cells. a, Pairwise 676 
replicate correlation (Pearson r) heatmap and unsupervised clustering of phosphoproteome 677 
data. b, KSEA of phosphoproteome data for RIT1WT and RIT1M90I-expressing cells. The kinase 678 
z-score indicates the overall score for each kinase listed, normalized by the total number of 679 
substrates. Significant scores (p<0.05) are indicated in red and blue. Phospho-sites of kinases 680 
in red were more highly abundant in the cell line compared to vector control, whereas phospho-681 
sites of kinases in blue were more highly abundant in vector control than the indicated cell line. 682 
c, KSEA of phosphoproteome data for KRAS-expressing cells. Labeling as in (b). d, Violin plot 683 
of phospho-site abundance of AKT1 substrate sites. e, Violin plot of phospho-site abundance of 684 
PRKCA substrate sites. f, Violin plot of phospho-site abundance of AURKB substrate sites. g, 685 
EGFR protein abundance in LC-MS/MS data compared to vector control. f, Proportion of 686 
phosphorylated sites in AHNAK proteins with differential phosphorylation between KRAS-mutant 687 
and RIT1M90I-mutant cells. Data shown is the percentage of differentially abundant 688 
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phosphorylation sites in AHNAK and AHNAK2 compared to all other sites. Significance was 689 
determined from the analysis in (b), FDR < 0.05. ****, p < 0.0001 by two-sided Fisher’s exact 690 
test. 691 
  692 
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